Genomic Study for Determination of Precise dose of Isoniazid in TB Patients.
Not Applicable
- Conditions
- Health Condition 1: A19- Miliary tuberculosisHealth Condition 2: A150- Tuberculosis of lungHealth Condition 3: A17- Tuberculosis of nervous systemHealth Condition 4: A18- Tuberculosis of other organs
- Registration Number
- CTRI/2019/05/019105
- Lead Sponsor
- evin Thomas
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed with TB.
2. Patients who are under minimum three days of Isoniazid therapy.
3. Age more than 18 years and less than 70 years.
4. Patients who are willing to give informed consent.
Exclusion Criteria
1. Vulnerable patients: Pregnant women and mentally challenged patients.
2. HIV positive patients.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method